NYSE:NVRO - Nevro Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $178.92
  • Forecasted Upside: 1.70 %
  • Number of Analysts: 13
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 10 Buy Ratings
  • 0 Strong Buy Ratings
$175.93
▼ -0.39 (-0.22%)
1 month | 3 months | 12 months
Get New Nevro Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NVRO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NVRO

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$178.92
▲ +1.70% Upside Potential
This price target is based on 13 analysts offering 12 month price targets for Nevro in the last 3 months. The average price target is $178.92, with a high forecast of $215.00 and a low forecast of $100.00. The average price target represents a 1.70% upside from the last price of $175.93.
Buy
The current consensus among 13 polled investment analysts is to buy stock in Nevro. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 1 sell ratings
8/5/2019
  • 0 strong buy ratings
  • 7 buy ratings
  • 4 hold ratings
  • 0 sell ratings
11/3/2019
  • 0 strong buy ratings
  • 8 buy ratings
  • 4 hold ratings
  • 0 sell ratings
2/1/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 4 hold ratings
  • 0 sell ratings
5/1/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 4 hold ratings
  • 0 sell ratings
7/30/2020
  • 0 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 0 sell ratings
10/28/2020
  • 0 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 0 sell ratings
12/27/2020
  • 0 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 0 sell ratings
1/26/2021

Latest Recommendations

  • 0 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/19/2021Canaccord GenuityBoost Price TargetBuy$167.00 ➝ $203.00Medium
i
1/19/2021SVB LeerinkBoost Price TargetPositive ➝ Outperform$190.00 ➝ $210.00Medium
i
1/6/2021TruistBoost Price Target$175.00 ➝ $205.00N/A
i
1/5/2021Robert W. BairdBoost Price TargetOutperform$180.00 ➝ $200.00N/A
i
1/4/2021Wells Fargo & CompanyBoost Price TargetOverweight$177.00 ➝ $215.00N/A
i
12/31/2020GuggenheimBoost Price TargetBuy$190.00 ➝ $205.00N/A
i
12/15/2020Morgan StanleyBoost Price TargetOverweight$161.00 ➝ $192.00Medium
i
11/11/2020JMP SecuritiesReiterated RatingOutperform$150.00 ➝ $190.00Low
i
11/6/2020Morgan StanleyBoost Price TargetOverweight$150.00 ➝ $161.00Low
i
10/22/2020GuggenheimInitiated CoverageBuy$190.00Low
i
10/21/2020OTR GlobalUpgradePositiveLow
i
10/12/2020SVB LeerinkBoost Price TargetOutperform$165.00 ➝ $175.00Low
i
9/1/2020Robert W. BairdInitiated CoverageOutperform$160.00Low
i
8/6/2020Canaccord GenuityBoost Price TargetBuy$116.00 ➝ $153.00Medium
i
8/6/2020Morgan StanleyBoost Price TargetOverweight$145.00 ➝ $150.00Medium
i
8/6/2020Wells Fargo & CompanyBoost Price TargetOverweight$141.00 ➝ $153.00High
i
8/6/2020SVB LeerinkBoost Price TargetOutperform$140.00 ➝ $165.00High
i
8/6/2020CitigroupBoost Price TargetBuy$137.00 ➝ $160.00High
i
8/5/2020OppenheimerInitiated CoverageHoldHigh
i
Rating by Suraj Kalia at Oppenheimer Holdings Inc.
6/18/2020Morgan StanleyBoost Price Target$135.00 ➝ $145.00High
i
6/18/2020CitigroupBoost Price TargetOverweight$135.00 ➝ $145.00High
i
6/8/2020UBS GroupUpgradeSell ➝ Neutral$100.00 ➝ $132.00High
i
6/4/2020SunTrust BanksReiterated RatingBuy$135.00High
i
Rating by Kaila Krum at SunTrust Banks, Inc.
5/6/2020SunTrust BanksBoost Price TargetBuy$120.00 ➝ $135.00Medium
i
5/6/2020Morgan StanleyBoost Price TargetOverweight$113.00 ➝ $135.00Medium
i
5/6/2020JPMorgan Chase & Co.Boost Price TargetNeutral$90.00 ➝ $100.00Low
i
5/6/2020CitigroupBoost Price TargetBuy$130.00 ➝ $137.00Low
i
4/3/2020Morgan StanleyLower Price TargetOverweight$118.00 ➝ $113.00Low
i
4/2/2020JPMorgan Chase & Co.Lower Price TargetNeutral$130.00 ➝ $90.00High
i
4/2/2020Canaccord GenuityLower Price TargetBuy$153.00 ➝ $114.00High
i
4/2/2020SunTrust BanksLower Price TargetBuy$146.00 ➝ $120.00High
i
4/2/2020Wells Fargo & CompanyLower Price TargetOverweight$158.00 ➝ $126.00High
i
Rating by Larry Biegelsen at Wells Fargo & Company
3/27/2020Morgan StanleyLower Price TargetOverweight$142.00 ➝ $118.00Low
i
3/27/2020CitigroupLower Price TargetBuy$160.00 ➝ $130.00High
i
3/4/2020CitigroupInitiated CoverageBuy$160.00Low
i
2/26/2020SVB LeerinkBoost Price TargetOutperform ➝ Positive$146.00 ➝ $158.00High
i
2/26/2020Wells Fargo & CompanyBoost Price TargetOverweight$144.00 ➝ $158.00High
i
Rating by Larry Biegelsen at Wells Fargo & Company
2/26/2020JPMorgan Chase & Co.Boost Price TargetNeutral$96.00 ➝ $130.00High
i
2/26/2020Canaccord GenuityUpgradeHold ➝ Buy$120.00 ➝ $153.00High
i
1/27/2020Morgan StanleyBoost Price TargetOverweight$125.00 ➝ $142.00High
i
Rating by David Lewis at Morgan Stanley
1/27/2020JMP SecuritiesBoost Price TargetOutperform$115.00 ➝ $150.00High
i
Rating by David Turkaly at JMP Securities
1/21/2020Wells Fargo & CompanyBoost Price TargetOverweight$135.00 ➝ $144.00Low
i
Rating by Larry Biegelsen at Wells Fargo & Company
1/15/2020UBS GroupBoost Price TargetSell$77.00 ➝ $84.00High
i
1/7/2020SunTrust BanksInitiated CoverageBuy$132.00Low
i
1/6/2020OppenheimerReiterated RatingOutperform ➝ Market PerformN/A
i
12/20/2019JPMorgan Chase & Co.Boost Price TargetNeutral$80.00 ➝ $96.00Low
i
12/17/2019Morgan StanleyBoost Price TargetOverweight$100.00 ➝ $125.00Low
i
Rating by David Lewis at Morgan Stanley
11/7/2019Canaccord GenuityBoost Price TargetHold ➝ Hold$59.00 ➝ $88.00High
i
11/7/2019OppenheimerUpgradeMarket Perform ➝ Outperform$106.00High
i
11/7/2019Wells Fargo & CompanyBoost Price TargetOutperform$86.00 ➝ $105.00High
i
Rating by Larry Biegelsen at Wells Fargo & Company
11/7/2019JMP SecuritiesBoost Price TargetOutperform$115.00High
i
Rating by David Turkaly at JMP Securities
10/22/2019OppenheimerInitiated CoverageMarket PerformHigh
i
10/9/2019Wells Fargo & CompanyBoost Price TargetOutperform$70.00 ➝ $86.00Low
i
8/23/2019SVB LeerinkSet Price TargetBuy$98.00Medium
i
Rating by Danielle Antalffy at SVB Leerink LLC
8/12/2019JMP SecuritiesBoost Price TargetMarket Outperform$70.00 ➝ $90.00High
i
8/9/2019Morgan StanleySet Price TargetBuy$76.00Medium
i
Rating by David Lewis at Morgan Stanley
8/9/2019Northland SecuritiesSet Price TargetHold$65.00Medium
i
Rating by Suraj Kalia at Northland Securities
8/9/2019Bank of AmericaBoost Price TargetBuy$70.00 ➝ $74.00N/A
i
8/9/2019Canaccord GenuityBoost Price TargetHold$50.00 ➝ $59.00High
i
5/13/2019Wells Fargo & CompanyLower Price TargetOutperform$75.00 ➝ $70.00Low
i
5/10/2019Morgan StanleyLower Price TargetOverweight$70.00 ➝ $64.00High
i
5/10/2019JMP SecuritiesLower Price TargetMarket Outperform$80.00 ➝ $70.00High
i
5/10/2019Canaccord GenuityDowngradeBuy ➝ Hold$62.00 ➝ $50.00High
i
3/20/2019Morgan StanleyUpgradeUnderweight ➝ Overweight$41.00 ➝ $70.00High
i
3/20/2019Wells Fargo & CompanyUpgradeMarket Perform ➝ Outperform$75.00High
i
3/20/2019Canaccord GenuityBoost Price TargetBuy$46.00 ➝ $62.00High
i
3/20/2019Bank of AmericaUpgradeNeutral ➝ Buy$50.00 ➝ $70.00High
i
3/19/2019BMO Capital MarketsUpgradeMarket Perform ➝ Outperform$46.00 ➝ $67.00High
i
2/22/2019BMO Capital MarketsDowngradeOutperform ➝ Market PerformHigh
i
1/11/2019Northland SecuritiesReiterated RatingHold$48.00Low
i
1/2/2019Morgan StanleyLower Price TargetUnderweight ➝ Underweight$43.00 ➝ $38.00High
i
11/27/2018UBS GroupInitiated CoverageSell ➝ Sell$35.00Low
i
11/7/2018Bank of AmericaDowngradeBuy ➝ NeutralHigh
i
11/6/2018Morgan StanleyDowngradeEqual ➝ Equal Weight$65.00 ➝ $43.00High
i
11/6/2018BMO Capital MarketsLower Price TargetOutperform ➝ Outperform$76.00 ➝ $60.00High
i
11/6/2018Canaccord GenuityLower Price TargetBuy ➝ In-Line$80.00 ➝ $63.00High
i
11/6/2018Wells Fargo & CompanyLower Price TargetMarket Perform ➝ Market Perform$62.00 ➝ $50.00High
i
11/6/2018JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$77.00 ➝ $45.00High
i
Rating by Robert Marcus at JPMorgan Chase & Co.
10/19/2018The Goldman Sachs GroupDowngradeNeutral ➝ Sell$60.00 ➝ $44.00High
i
Rating by Isaac Ro at The Goldman Sachs Group, Inc.
8/6/2018BMO Capital MarketsLower Price TargetOutperform ➝ Outperform$80.00 ➝ $76.00High
i
7/17/2018Bank of AmericaLower Price TargetBuy ➝ Buy$102.00 ➝ $77.00Low
i
7/17/2018Wells Fargo & CompanyLower Price TargetMarket Perform ➝ Market Perform$84.00 ➝ $62.00Low
i
7/17/2018SVB LeerinkLower Price TargetOutperform ➝ Outperform$95.00 ➝ $90.00Low
i
7/17/2018Morgan StanleyLower Price TargetEqual Weight ➝ Equal Weight$88.00 ➝ $65.00Low
i
7/16/2018Canaccord GenuityLower Price TargetBuy ➝ Buy$102.00 ➝ $83.00High
i
7/11/2018JPMorgan Chase & Co.Reiterated RatingBuyLow
i
Rating by Robert Marcus at JPMorgan Chase & Co.
7/2/2018Morgan StanleyDowngradeOverweight ➝ Equal Weight$95.00High
i
5/8/2018Canaccord GenuityLower Price TargetBuy ➝ Buy$110.00 ➝ $102.00High
i
5/8/2018JMP SecuritiesReiterated RatingMarket Outperform ➝ Overweight$120.00 ➝ $105.00High
i
5/8/2018Northland SecuritiesDowngradeOutperform ➝ Market PerformHigh
i
5/8/2018Wells Fargo & CompanyDowngradeOutperform ➝ Market PerformHigh
i
4/4/2018The Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$83.00Low
i
Rating by Issac Ro at The Goldman Sachs Group, Inc.
12/14/2017BMO Capital MarketsReiterated RatingBuy$100.00High
i
11/7/2017Canaccord GenuityLower Price TargetBuy$120.00 ➝ $110.00N/A
i
11/7/2017Northland SecuritiesReiterated RatingBuy$96.00N/A
i
11/7/2017SVB LeerinkReiterated RatingOutperform$105.00 ➝ $110.00N/A
i
10/8/2017Canaccord GenuityReiterated RatingBuy$120.00N/A
i
9/1/2017BMO Capital MarketsReiterated RatingBuy$106.00N/A
i
8/8/2017Northland SecuritiesReiterated RatingBuy$96.00High
i
8/8/2017Morgan StanleyBoost Price TargetOverweight$87.00 ➝ $95.00Medium
i
7/5/2017Canaccord GenuityReiterated RatingBuy$120.00High
i
7/3/2017JPMorgan Chase & Co.Reiterated RatingOverweight$102.00Low
i
6/15/2017Northland SecuritiesSet Price TargetBuy$96.00Low
i
5/14/2017B. RileyDowngradeNeutral$85.00Low
i
Rating by G. Chodaczek at B. Riley
5/9/2017B. RileyDowngradeBuy ➝ Neutral$108.00 ➝ $85.00High
i
Rating by G. Chodaczek at B. Riley
5/9/2017Northland SecuritiesReiterated RatingBuy$96.00High
i
3/23/2017Canaccord GenuityInitiated CoverageBuy$120.00Medium
i
3/1/2017B. RileyReiterated RatingBuy$108.00N/A
i
Rating by greg chodaczek at B. Riley
2/24/2017B. RileyReiterated RatingBuy$108.00N/A
i
Rating by greg chodaczek at B. Riley
2/24/2017SVB LeerinkBoost Price TargetOutperform$100.00 ➝ $110.00N/A
i
2/2/2017Northland SecuritiesReiterated RatingPositive$110.00N/A
i
1/30/2017Northland SecuritiesUpgradeMarket Perform ➝ Outperform$110.00N/A
i
11/13/2016B. RileyReiterated RatingBuy$102.00N/A
i
Rating by greg chodaczek at B. Riley
11/8/2016B. RileyReiterated RatingBuy$102.00N/A
i
Rating by greg chodaczek at B. Riley
9/21/2016B. RileyInitiated CoverageBuy$114.00N/A
i
Rating by greg chodaczek at B. Riley
9/16/2016B. RileyReiterated RatingBuyN/A
i
Rating by G. Chodaczek at B. Riley
9/15/2016B. RileyInitiated CoverageBuy$114.00N/A
i
8/11/2016Piper Jaffray CompaniesReiterated RatingOverweight$98.00 ➝ $112.00N/A
i
8/9/2016JPMorgan Chase & Co.Boost Price TargetOverweight$84.00 ➝ $100.00N/A
i
Rating by Michael Weinstein at JPMorgan Chase & Co.
8/9/2016JMP SecuritiesBoost Price TargetMarket Outperform$90.00 ➝ $110.00N/A
i
8/9/2016BMO Capital MarketsReiterated RatingBuy$100.00N/A
i
8/8/2016Bank of AmericaInitiated CoverageBuy$100.00N/A
i
7/22/2016Piper Jaffray CompaniesInitiated CoverageOverweight$98.00N/A
i
7/19/2016William BlairInitiated CoverageOutperformN/A
i
7/18/2016William BlairReiterated RatingOutperformN/A
i
Rating by M. Kaczor at William Blair
7/12/2016Wells Fargo & CompanyInitiated CoverageOutperformN/A
i
6/29/2016Morgan StanleyReiterated RatingBuy$86.00N/A
i
Rating by David Lewis at Morgan Stanley
6/6/2016SVB LeerinkReiterated RatingBuyN/A
i
Rating by Danielle Antalffy at SVB Leerink LLC
5/16/2016Sterne Agee CRTReiterated RatingBuyN/A
i
Rating by G. Chodaczek at Sterne Agee CRT
5/10/2016SVB LeerinkReiterated RatingBuyN/A
i
Rating by Danielle Antalffy at SVB Leerink LLC
5/10/2016Morgan StanleyReiterated RatingBuyN/A
i
Rating by David Lewis at Morgan Stanley
5/10/2016BMO Capital MarketsReiterated RatingBuy$79.00N/A
i
4/27/2016Morgan StanleyReiterated RatingOverweight$86.00N/A
i
Rating by David Lewis at Morgan Stanley
4/17/2016Morgan StanleyReiterated RatingBuyN/A
i
Rating by David Lewis at Morgan Stanley
4/2/2016JPMorgan Chase & Co.Reiterated RatingBuyN/A
i
Rating by Michael Weinstein at JPMorgan Chase & Co.
3/29/2016Northland SecuritiesInitiated CoverageMarket Perform$48.00N/A
i
3/1/2016SVB LeerinkReiterated RatingBuy$75.00 ➝ $80.00N/A
i
Rating by Danielle Antalffy at SVB Leerink LLC
3/1/2016BMO Capital MarketsBoost Price TargetOutperform$76.00 ➝ $78.00N/A
i
1/27/2016JMP SecuritiesBoost Price TargetMarket Outperform$78.00 ➝ $85.00N/A
i
(Data available from 1/27/2016 forward)
Nevro logo
Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. It also offers Senza II system and Senza Omnia system products for chronic pain. The company's solution for chronic pain also includes HF10 Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. Nevro Corp. sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was founded in 2006 and is headquartered in Redwood City, California.
Read More

Today's Range

Now: $175.93
$173.98
$178.31

50 Day Range

MA: $173.82
$161.99
$184.34

52 Week Range

Now: $175.93
$65.05
$188.14

Volume

293,042 shs

Average Volume

579,322 shs

Market Capitalization

$6.06 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.02

Frequently Asked Questions

What sell-side analysts currently cover shares of Nevro?

The following Wall Street research analysts have issued stock ratings on Nevro in the last year: Canaccord Genuity, Citigroup Inc., Guggenheim, JMP Securities, JPMorgan Chase & Co., Morgan Stanley, Oppenheimer Holdings Inc., OTR Global, Robert W. Baird, SunTrust Banks, Inc., SVB Leerink LLC, TheStreet, Truist, UBS Group AG, Wells Fargo & Company, and Zacks Investment Research.

What is the current price target for Nevro?

12 Wall Street analysts have set twelve-month price targets for Nevro in the last year. Their average twelve-month price target is $178.92, suggesting a possible upside of 1.5%. Wells Fargo & Company has the highest price target set, predicting NVRO will reach $215.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $100.00 for Nevro in the next year.

What is the current consensus analyst rating for Nevro?

Nevro currently has 3 hold ratings and 10 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe NVRO will outperform the market and that investors should add to their positions of Nevro.

What other companies compete with Nevro?

How do I contact Nevro's investor relations team?

Nevro's physical mailing address is 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065. The medical equipment provider's listed phone number is 650-251-0005 and its investor relations email address is [email protected] The official website for Nevro is www.nevro.com.